{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:24:08Z","timestamp":1793118248258,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Phospholipid Research Center, Heidelberg, Germany"},{"name":"European Union Seventh Framework Program","award":["NMP-2012-309820"],"award-info":[{"award-number":["NMP-2012-309820"]}]},{"name":"European Union Seventh Framework Program","award":["NMP-2013-602923"],"award-info":[{"award-number":["NMP-2013-602923"]}]},{"name":"Hungarian Scientific Research","award":["K-113164"],"award-info":[{"award-number":["K-113164"]}]},{"name":"Miskolc University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jconrel.2019.07.005","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T11:14:32Z","timestamp":1562584472000},"page":"333-338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs"],"prefix":"10.1016","volume":"309","author":[{"given":"Tam\u00e1s","family":"F\u00fcl\u00f6p","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely T.","family":"Kozma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"Vashegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"M\u00e9sz\u00e1ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Rosivall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Urbanics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Storm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josbert M.","family":"Metselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Szebeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2019.07.005_bb0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.29016\/180427.1","article-title":"A porcine model of complement activation-related pseudoallergy to nano-pharmaceuticals: pros and cons of translation to a preclinical safety test","volume":"1","author":"Szebeni","year":"2018","journal-title":"Prec. Nanomed."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0010","first-page":"H1319","article-title":"Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction","volume":"279","author":"Szebeni","year":"2000","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0015","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.2174\/138161208786369786","article-title":"Hypersensitivity reactions to last generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use","volume":"14","author":"Calogiuri","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejps.2013.03.007","article-title":"Complement activation by PEGylated liposomes containing prednisolone","volume":"49","author":"van den Hoven","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0025","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.nano.2015.02.021","article-title":"Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration","volume":"11","author":"van der Valk","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0030","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.nano.2016.02.022","article-title":"Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis","volume":"12","author":"van der Valk","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0035","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1161\/01.CIR.99.17.2302","article-title":"Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody","volume":"99","author":"Szebeni","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1515\/ejnm-2015-0011","article-title":"Lessons learned from the porcine CARPA model: constant and variable responses to different nanomedicines and administration protocols","volume":"7","author":"Urbanics","year":"2015","journal-title":"Eur J Nanomedicine"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0045","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nano.2011.06.003","article-title":"Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome","volume":"8","author":"Szebeni","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0050","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jconrel.2012.02.029","article-title":"Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model","volume":"160","author":"Szebeni","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0055","first-page":"250","article-title":"Monoclonal antibodies, immunogenicity, and associated infusion reactions","volume":"72","author":"Cheifetz","year":"2005","journal-title":"Mt Sinai J. Med."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0060","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.gtc.2006.09.006","article-title":"Infusion reactions and their management","volume":"35","author":"Mayer","year":"2006","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0065","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41565-018-0273-1","article-title":"Roadmap and strategy for overcoming infusion reactions to nanomedicines","volume":"13","author":"Szebeni","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2019.07.005_bb0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000232882","article-title":"Possible role of serum anaphylatoxins in hypersensitivity reactions","volume":"66","author":"Hugli","year":"1981","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0080","doi-asserted-by":"crossref","first-page":"H1050","DOI":"10.1152\/ajpheart.00622.2005","article-title":"Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function","volume":"290","author":"Szebeni","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0085","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.2147\/IJN.S161369","article-title":"Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization","volume":"13","author":"Meszaros","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0090","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2147\/IJN.S187139","article-title":"Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice","volume":"14","author":"Orfi","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0095","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.drudis.2018.01.025","article-title":"Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?","volume":"23","author":"Szebeni","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0100","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1080\/14740338.2016.1218467","article-title":"Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise","volume":"15","author":"Hermanson","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0105","unstructured":"Krystexxa\u00ae (pegloticase injection), for intravenous infusion: Prescribing Information Revised 2018, https:\/\/hznp.azureedge.net\/public\/KRYSTEXXA_Prescribing_Information.pdf, (2018)."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0110","author":"Krystexxa"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0115","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/eurheartj\/ehs232","article-title":"A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial","volume":"34","author":"Povsic","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0120","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.drudis.2017.11.006","article-title":"Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection\/infusion reactions","volume":"23","author":"Moghimi","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0125","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2217\/nnm-2018-0064","article-title":"Translational gaps in animal models of human infusion reactions to nanomedicines","volume":"13","author":"Moghimi","year":"2018","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0130","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.119.258012","article-title":"The interplay between blood proteins, complement, and macrophages on nanomedicine performance and responses","author":"Moghimi","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0135","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nnano.2017.47","article-title":"Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes","volume":"12","author":"Wibroe","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0140","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2010.03.011","article-title":"Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death","volume":"146","author":"Epstein-Barash","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2017.08.010","article-title":"Immunological response to nitroglycerin-loaded shear-responsive liposomes in vitro and in vivo","volume":"264","author":"Buscema","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0150","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.2147\/IJN.S138108","article-title":"Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging","volume":"12","author":"Unterweger","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0155","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2147\/IJN.S156528","article-title":"Dextran-coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging: evaluation of size-dependent imaging properties, storage stability and safety","volume":"13","author":"Unterweger","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0160","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2217\/nnm.15.216","article-title":"Nanoparticles for intravascular applications: physicochemical characterization and cytotoxicity testing","volume":"11","author":"Matuszak","year":"2016","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0165","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/cvr\/cvy219","article-title":"From design to the clinic: practical guidelines for translating cardiovascular nanomedicine","volume":"114","author":"Cicha","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0170","series-title":"US Patent Applicationsd #20160122759","article-title":"Dosages and methods for delivering lipid formulated nucleic acid molecules","author":"Kasperovic","year":"2016"},{"key":"10.1016\/j.jconrel.2019.07.005_bb0175","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1111\/bph.13268","article-title":"Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management","volume":"172","author":"Szebeni","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.07.005_bb0180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1348-0421.2002.tb02669.x","article-title":"Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N","volume":"46","author":"Campbell","year":"2002","journal-title":"Microbiol. Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591930392X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591930392X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:45:52Z","timestamp":1759160752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591930392X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":36,"alternative-id":["S016836591930392X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.07.005","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}